Cargando…

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab

Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn’s disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the α4β7 integrin. Since α4β7-expressing lymphocytes mainly infiltrate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scarozza, Patrizio, Marafini, Irene, Laudisi, Federica, Troncone, Edoardo, Schmitt, Heike, Lenti, Marco Vincenzo, Costa, Stefania, Rocchetti, Irene, De Cristofaro, Elena, Salvatori, Silvia, Frezzati, Ludovica, Di Sabatino, Antonio, Atreya, Raja, Neurath, Markus F., Calabrese, Emma, Monteleone, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073927/ https://www.ncbi.nlm.nih.gov/pubmed/32024071 http://dx.doi.org/10.3390/jcm9020385

Ejemplares similares

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis
por: Marafini, Irene, et al.
Publicado: (2021)

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Marafini, Irene, et al.
Publicado: (2021)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms
por: Salvatori, Silvia, et al.
Publicado: (2023)

Interleukin-34 promotes tumorigenic signals for colon cancer cells
por: Franzè, Eleonora, et al.
Publicado: (2021)

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Role of Interleukin-34 in Cancer
por: Franzè, Eleonora, et al.
Publicado: (2020)

Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
por: De Cristofaro, Elena, et al.
Publicado: (2022)

Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy
por: Lolli, Elisabetta, et al.
Publicado: (2022)

Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids
por: De Cristofaro, Elena, et al.
Publicado: (2021)

Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders
por: Teofani, Adelaide, et al.
Publicado: (2022)

Low frequency of COVID-19 in inflammatory bowel diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Transforming Growth Factor-β1/Smad7 in Intestinal Immunity, Inflammation, and Cancer
por: Troncone, Edoardo, et al.
Publicado: (2018)

Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer
por: Troncone, Edoardo, et al.
Publicado: (2021)

Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer
por: Stolfi, Carmine, et al.
Publicado: (2020)

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
por: Marafini, Irene, et al.
Publicado: (2021)

Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
por: Becker, Emily, et al.
Publicado: (2022)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Frequency and Predictors of Dysplasia in Pseudopolyp-like Colorectal Lesions in Patients with Long-Standing Inflammatory Bowel Disease
por: De Cristofaro, Elena, et al.
Publicado: (2023)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Metalloproteinases in Inflammatory Bowel Diseases
por: Marônek, Martin, et al.
Publicado: (2021)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors
por: Troncone, Edoardo, et al.
Publicado: (2020)

Targeting IL-34/MCSF-1R Axis in Colon Cancer
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Protective Effects of Aryl Hydrocarbon Receptor Signaling in Celiac Disease Mucosa and in Poly I:C-Induced Small Intestinal Atrophy Mouse Model
por: Dinallo, Vincenzo, et al.
Publicado: (2019)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Precision Medicine in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2021)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
por: Salvatori, Silvia, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
por: Haga, Keiichi, et al.
Publicado: (2022)

High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Orbital Myositis in a Patient With Ileal Crohn's Disease in Remission on Vedolizumab
por: Sandhu, Sunny, et al.
Publicado: (2022)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dpj9da5ah6ljhdov9j4oehvtsf